PROCEPT BioRobotics recently reported two major milestones in its WATER IV prostate cancer program, completing enrollment in the randomized WATER IV RP trial comparing Aquablation therapy with radical ...

PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Get the latest news on PROCEPT BioRobotics stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on PROCEPT BioRobotics performance ...

The demand for robotics and automation continues to grow, particularly following the pandemic. As labor costs have escalated, companies have invested in labor-saving measures. Market forecasts project ...

Case Western Reserve roboticist Roger Quinn, neuroscientist Hillel Chiel to lead $8 million, five-year National Science Foundation NeuroNex Network project seeking next level of control of ...

Procept BioRobotics reported a 55% year-over-year revenue increase in the first quarter, reaching $69.2 million. The company’s HydroS robotic system aims to streamline procedures with AI-powered ...

The next frontier in robotics will take inspiration from biology to design robots that are soft, smart, green and social. From microrobots for cancer treatment, to swarms powering warehouses, soft ...

PROCEPT BioRobotics (NASDAQ:PRCT) stock is trading on Monday after the company released better-than-expected third-quarter earnings. The company reported EPS loss of $(0.40), down from $(0.51) a year ...